Is Amanta Healthcare the Best Stock in Its Sector? A Look at the Numbers
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Amanta Healthcare CMP Rs 186 (23 Sep 2026). Market cap Rs 718 Cr. ROE 7.46%. P/E 48.94x versus Industry P/E 51.81x.
Quick Answer
Amanta Healthcare is one of the names investors compare when screening the Healthcare sector, built on a 7.46% return on equity and a P/E of 48.94x against an Industry P/E of 51.81x. Whether Amanta Healthcare is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Amanta Healthcare the best stock in its sector? The stock trades on the NSE at Rs 186 as of 23 September 2026, within its 52-week range of Rs 92.00 to Rs 209.95. Amanta Healthcare Ltd manufactures sterile intravenous fluids and injectable pharmaceutical formulations.
Amanta Healthcare sits in the Healthcare sector, and its 7.46% ROE and 48.94x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Amanta Healthcare
Amanta Healthcare Ltd manufactures sterile intravenous fluids and injectable pharmaceutical formulations. It manufactures sterile intravenous fluids and injectable formulations, a specialised, capital-intensive corner of pharma manufacturing distinct from oral solid formulations. At a market capitalisation of Rs 718 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Amanta Healthcare the Best Stock in Its Sector?
Amanta Healthcare makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 7.46% ROE with a 48.94x P/E against the sector’s 51.81x Industry P/E. Amanta Healthcare trades close to its 51.81x Industry P/E, with a 7.46% ROE that trails Anthem Biosciences and Akums Drugs and Pharmaceuticals in this series, reflecting the capital-intensive nature of sterile IV fluid manufacturing.
| Metric | Amanta Healthcare |
|---|---|
| CMP (NSE) | Rs 185.50 |
| 52-Week High / Low | Rs 209.95 / Rs 92.00 |
| Market Cap | Rs 718 Cr |
| P/E (TTM) vs Industry P/E | 48.94x vs 51.81x |
| P/B | 3.26 |
| ROE | 7.46% |
| EPS (TTM) | Rs 3.78 |
| Dividend Yield | 0.00% |
| Debt to Equity | 1.11 |
Compare Amanta Healthcare Against Other Healthcare Sector Stocks
How Amanta Healthcare Compares Against Its Healthcare Sector Peers
The table below sets Amanta Healthcare against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Amanta Healthcare | 718 | 48.94 | 7.46% | 1.11 |
| Anthem Biosciences | 50,236 | 87.26 | 19.45% | 0.02 |
| Akums Drugs and Pharmaceuticals | 12,059 | 41.19 | 7.70% | 0.05 |
| Aarti Pharmalabs | 7,157 | 34.39 | 8.89% | 0.38 |
| Peer average (3 companies) | – | 54.28 | 12.01% | 0.15 |
Against this peer set, Amanta Healthcare’s 7.46% ROE is below the 12.01% peer average, and its P/E of 48.94x runs below the peer average of 54.28x. Amanta Healthcare trades close to its 51.81x Industry P/E, with a 7.46% ROE that trails Anthem Biosciences and Akums Drugs and Pharmaceuticals in this series, reflecting the capital-intensive nature of sterile IV fluid manufacturing.
What Makes Amanta Healthcare Worth Watching in Healthcare
- Close to Industry P/E: A 48.94x P/E versus a 51.81x Industry P/E shows the stock trading close to Healthcare sector norms.
- Specialised IV fluids manufacturing: Manufacturing sterile intravenous fluids requires specialised regulatory approvals and manufacturing standards that differentiate Amanta from generic formulation makers.
- Higher leverage for sterile manufacturing: A debt to equity ratio of 1.11 reflects the capital intensity of sterile injectable manufacturing facilities.
Amanta Healthcare Valuation: Is It Justified?
Amanta Healthcare trades close to its 51.81x Industry P/E, with a 7.46% ROE that trails Anthem Biosciences and Akums Drugs and Pharmaceuticals in this series, reflecting the capital-intensive nature of sterile IV fluid manufacturing. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Allied Blenders and Distillers the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Amanta Healthcare and other Healthcare sector stocks.
How to Track Amanta Healthcare Before You Invest
Before deciding whether Amanta Healthcare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Amanta Healthcare to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Amanta Healthcare earns a place in the best stock in its sector conversation on the strength of a 7.46% ROE and a P/E of 48.94x against a 51.81x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Amanta Healthcare the best stock in its sector?
Ans. Amanta Healthcare has a 7.46% ROE and trades at 48.94x P/E against a 51.81x Industry P/E, and compares below the peer average ROE of 12.01% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Amanta Healthcare?
Ans. Amanta Healthcare was trading at Rs 185.50 on the NSE as of 23 September 2026, within its 52-week range of Rs 92.00 to Rs 209.95.
What sector does Amanta Healthcare belong to?
Ans. Amanta Healthcare is classified under the Healthcare sector on Univest.
How does Amanta Healthcare compare to its sector peers on P/E?
Ans. Amanta Healthcare’s P/E of 48.94x is below the 54.28x average of the 3 named peers compared in this article.
What is Amanta Healthcare’s return on equity?
Ans. Amanta Healthcare reported a return on equity of 7.46%, which is below the 12.01% average of its named peers in this comparison.
Should I invest in Amanta Healthcare based on its sector position?
Ans. Amanta Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
